Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

How could relapse in leukemia after CAR T treatment—a problem that still affects between 30–60% of patients—be prevented? One major driver is antigen escape: leukemia cells can dial down or lose the ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

A fasting-derived ketone metabolite reshapes CAR T cell metabolism and gene activity, boosting immune cell expansion, energy ...

As a world leader in the immuno-oncology field, Dr. Zihai Li has long been at the forefront of cancer immunotherapy.

Fred Hutch Cancer Center hematologists took center stage at the 2026 Tandem Meetings, a multidisciplinary meeting of experts in the field of blood stem cell transplantation, held in Salt Lake City ...

The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve.

South University (SU) is proud to highlight a powerful example of its mission in action, as faculty from the SU Tampa ...

The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance ...